1Q22 Business Results
1Q22 Business Results
Income Statement
Revenue Notwithstanding the temporary sales reduction due to preparation for the direct-sales of additional products in Europe, the total
revenue increased YoY thanks to stable prescription of Truxima in the N.America market as well as steady growth of RemsimaⓇ SC
: Achieved sound operating profit due to sales increase in the profitable N.America market
OP
NP
: Increased YoY and QoQ as a result of the increase in the non-operating profit due to weak Won
(KRW bn)
'21.1Q
'21.4Q
'22.1Q
%YoY
%QoQ
Revenue
356.3
605.8
415.7
16.7%
-31.4%
Gross Profit
82.3
146.4
104.3
26.7%
-28.8%
(%)
23.1%
24.2%
25.1%
2.0%p
0.9%p
SG&A
50.8
76.7
59.2
16.5%
-22.8%
(%)
14.3%
12.7%
14.2%
-0.1%p
1.5%p
Personnel expenses
12.8
22.9
12.5
-2.3%
-45.4%
Research expenses
9.8
7.4
5.0
-49.0%
-32.4%
Advertising expenses
1.4
6.5
2.9
107.1%
-55.4%
Commissions
13.4
18.7
15.5
15.7%
-17.1%
Operating Profit
31.5
69.7
45.0
42.9%
-35.4%
(%)
8.8%
11.5%
10.8%
2.0%p
-0.7%p
EBIT
35.0
23.0
61.3
75.1%
166.5%
Net Profit
31.5
16.8
43.6
38.4%
159.5%
Investor Relations 2022 4View entire presentation